Pivekimab Sunirine
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for Pivekimab Sunirine, covering 2025-12-29 to 2026-04-14. Get the full timeline:
Most recent: Clinical Trial Update: Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK [IMGN632]) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms [Phase 1]